ClinicalTrials.gg
RecruitingNCT03903835ProBioUpdated Apr 9, 2025

ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer

A Phase 3 interventional study of Enzalutamide Oral Capsule and Abiraterone Oral Tablet in Metastatic Castration-resistant Prostate Cancer (mCRPC) and Metastatic Hormone-Sensitive Prostate Cancer (mHSPC), sponsored by Karolinska Institutet. Recruiting at 32 sites in 4 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-09.

Sponsored by Karolinska Institutet · Phase 3, Interventional, and Treatment

How we know · 25 judgments

From the registry’s dates

  • Started Feb 2019; still recruiting 7 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
750
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 125 studies testing enzalutamide in Prostatic Neoplasms — 17 open to participants now, 38 under way, 9 of them phase 3. enzalutamide · Prostatic Neoplasms.

Planned enrollment
13th of 125
750 · median 52
Started
2019
with 6 others
Phase 3
16 of 125
1 open now
Primary completion
2026-12
later than 18 of 37 live
Registered
93rd of 125
by date

Among the 125 studies testing enzalutamide in Prostatic Neoplasms, this one is the 13th largest by planned enrollment, is one of 7 that started in 2019, is one of 16 in phase 3, reaches primary completion later than 18 of the 37 other live ones, and was the 93rd registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

17 of the 125 studies testing enzalutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About enzalutamide

enzalutamide: first FDA approval 2012 (XTANDI), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing enzalutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

ProBio is an international, outcome-adaptive, multi-arm, open-label, multiple assignment randomized biomarker driven platform trial in patients with metastatic prostate cancer. Patients will be randomized to control or experimental treatment arms. Patients in the control arm will receive standard of care following national guidelines. Patients in the experimental arm will be randomized to treatments based on a biomarker signature inferred from diagnostic tissue or liquid biopsy profiling. The predefined biomarker signatures are tumor properties or mutations in genes/pathways with previously demonstrated clinical validity (e.g. prognostic value or association with treatment response). The biomarker signatures are identified using a hybridisation capture gene panel specifically designed for prostate cancer.

Read the detailed description

ProBio is an outcome-adaptive, multi-arm, open-label, multiple assignment randomised biomarker driven platform trial in patients with metastatic hormone-sensitive and castration-resistant prostate cancer.

Patients will be randomised to control or experimental treatment class arms. Patients in the control arm will receive standard of care following national guidelines and will remain within the control arm throughout the course of the trial. Patients in the experimental arm will be randomised to a treatment class (consisting of one or multiple drugs) based on a biomarker signature. The biomarker signatures are defined as tumour properties or mutations in certain genes/pathways identified in the scientific literature as important in prostate cancer treatment response. The biomarker signatures are identified using a gene panel specifically designed for advanced prostate cancer.

Alterations in the following genes/pathways or combinations thereof constitute the biomarker signatures:

  • Androgen receptor
  • DNA-repair deficiency
  • TP53
  • TMPRSS2-ERG gene fusion
  • PI3K pathway alterations

Patients in the experimental arm can be randomized to the following treatments classes:

for mHSPC

  • AR signalling inhibitors (Abiraterone acetate, Enzalutamide, Apalutamide)
  • Taxane-based chemotherapy in combination with ARSi (Docetaxel plus Abiraterone acetate, or Darolutamide)
  • PolyADP Ribose Polymerase Inhibitors (Niraparib plus Abiraterone Acetate)

for mCRPC

  • AR signalling inhibitors (Enzalutamide, Abiraterone acetate)
  • Poly ADP Ribose Polymerase Inhibitors (Niraparib plus Abiraterone acetate)
  • Selective AKT Inhibitor (Capivasertib plus Docetaxel)

ProBio will use outcome-adaptive randomization, adapting the randomization based on the observed progression free survival (PFS) within biomarker signatures. Treatments will initially be assigned to patients based on the biomarker signatures for which that treatment is most likely to be effective. The trial will be analyzed within a Bayesian framework, which allows for calculations of the probability for each treatment that it is superior to standard of care within a given signature. Each experimental arm will be evaluated for efficacy relative to the control arm with the same biomarker signatures.

Participants and treating physicians will be blinded to ctDNA profile of each patient. The biomarker signatures will thus not influence treatment choice among controls (reflecting today's standard of care).

Further, ProBio will use the sequential multiple assignments trial (SMART) concept, where each patient who progresses within the trial will re-enter the trial and be re-assigned to another treatment based on the patient's current ctDNA profile. Patients will be withdrawn after in total maximal three randomized consecutive treatments after inclusion into the study.

The randomization probabilities within the experimental arm are defined in proportion to the probability that each treatment is superior to standard of care within a given biomarker signature, and therefore change as data accumulates in the trial and knowledge accumulates for what biomarker signatures and specific treatments that are more probable to be effective.

Trial results will be evaluated regularly by an independent data and safety monitoring board (DSMB). The DSMB will evaluate treatment-signature combinations with respect to:

  • Graduation for superiority: A treatment-biomarker signature combination will be graduated from the trial if it has a Bayesian predictive probability of success in a future confirmatory phase III trial exceeding a pre-specified threshold (85%).
  • Termination for futility: Treatment-biomarker signature combinations will be dropped from the trial for futility when success probabilities drop sufficiently low (less than 10% using a minimum of 20 patients assigned to the specific treatment-biomarker signature combination).
  • Alternatively, if the maximum sample size of 300 and 150 patients (for mHSPC and mCRPC, respectively) assigned to a treatment biomarker signature is reached without graduation for superiority, assignments to that combination will end.

ProBio is a platform study. This means that new treatments and biomarker signatures can be added to the experimental arm in the future. This will be done after protocol amendments.

03

Conditions studied

  • Metastatic Castration-resistant Prostate Cancer (mCRPC)
  • Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Browse trials for

Keywords

  • mCRPC
  • mHSPC
  • cfDNA
  • Genomics
  • Liquid Biopsy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Man with confirmed prostate adenocarcinoma, initiating systemic therapy for disease, encompassing newly diagnosed (i.e. de novo) hormone sensitive prostate cancer (mHSPC) or castration resistant prostate cancer (mCRPC)
  • Distant metastatic disease documented by positive bone scan or metastatic lesions on CT or MRI
  • Adequate health as assessed by the investigator to receive all available treatments in the trial
  • (Eastern Cooperative Oncology Group/ World Health Organization) performance score 0-2
  • Adequate organ and bone marrow function
  • Albumin greater than or equal to 28 g/L
  • Able to understand the patient information and sign written

Exclusion criteria

Exclusion Criteria:

  • Other within 5 years except non-melanoma skin cancer
  • Within 6 months of randomization: myocardial infarction, unstable angina, angioplasty, bypass surgery, stroke, (transient ischemic attack), or congestive heart failure (New York Heart Association) class III or IV
  • Uncontrolled hypertension
  • Uncontrolled hypotension
  • Received systemic therapy (with the exception of standard ADT) prior to study inclusion, for the CRPC indication
  • Any severe acute or chronic medical condition that places the patient at increased risk of serious toxicity or interferes with the interpretation of study results
  • Unable to comply with study procedures
  • Current participation in another clinical trial that will be in conflict with the present study, administration of an therapeutic or invasive surgical procedure within 28 days prior to study enrolment
  • Patients who are unlikely to comply with the protocol
  • Any condition or situation which, in the opinion of the investigator, would put the subject at risk, may confound study results, or interfere with the subjects participation in this study.
  • Any medical condition that would make use of the study treatments , according to the SmPC, e.g. significant heart or liver disease.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
750 participants (estimated)

Study arms

  • Active comparator
    Control: Standard Care

    Randomization between assignment to the control arm or the biomarker driven arm will be stratified on biomarker signatures, previous treatment, and fraction of ctDNA and will therefore occur after the results from the ctDNA profiling is obtained. Patients in the control arm will receive standard of care following national guidelines.

    Drug: Enzalutamide Oral Capsule · Drug: Abiraterone Oral Tablet · Drug: Cabazitaxel 60 mg Solution for Injection · Drug: Docetaxel Injectable Solution · Drug: Radium Chloride Ra-223 · Drug: Apalutamide

  • Experimental
    Treatment 1 in mHSPC: AR signalling inhibitors (ARSi)

    Assignments to therapy in the biomarker driven arms will be done on the basis of the biomarker signature using the current information about the efficacy of the various regimens for that signature. Information from previous studies may be incorporated in the randomization at study onset if such reliable data exists. Specifically, patients with an intact androgen receptor (AR) and without TP53 mutations will have increased chance of being randomized to treatment with ARSi.

    Drug: Enzalutamide Oral Capsule · Drug: Abiraterone Oral Tablet · Drug: Apalutamide

  • Experimental
    Treatment 2 in mHSPC: taxane-based chemotherapy in combination with ARSi

    Patients with TP53 mutations and TMPRSS2-ERG gene fusions will have an increased chance of being randomised to treatment with chemotherapy plus an ARSi.

    Drug: Abiraterone Oral Tablet · Drug: Docetaxel Injectable Solution · Drug: Darolutamide

  • Experimental
    Treatment 3 in mHSPC: Poly ADP Ribose Polymerase (PARP) inhibitor

    DNA-repair deficient patients will have an increased chance of receiving PARP inhibitors at study onset.

    Drug: Niraparib plus Abiraterone acetate plus Prednisone

  • Experimental
    Treatment 1 in mCRPC: AR signalling inhibitors (ARSi)

    Specifically, patients with an intact androgen receptor (AR) and without TP53 mutations will have increased chance of being randomized to treatment with ARSi.

    Drug: Enzalutamide Oral Capsule · Drug: Abiraterone Oral Tablet

  • Experimental
    Treatment 2 in mCRPC: Poly ADP Ribose Polymerase (PARP) inhibitor

    DNA-repair deficient patients will have an increased chance of receiving PARP inhibitors at study onset.

    Drug: Niraparib plus Abiraterone acetate plus Prednisone

  • Experimental
    Treatment 3 in mCRPC: selective AKT Inhibitor

    Patients with alterations in the PI3K pathway will have an increased chance of receiving the combination treatment with Capivasertib plus Docetaxel.

    Drug: Capivasertib plus Docetaxel

  • Experimental
    Treatment 4 in mCRPC: Carboplatin

    Only patients with DNA-repair deficiency will be treated with Carboplatin as second line treatment in the castration-resistant phase of ProBio.

    Drug: Carboplatin

Interventions

  • DrugEnzalutamideStudies of EnzalutamideEnzalutamide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Detailed conditions for the use of the study treatments including dose and dosages are described in accordance with the marketing authorization in the SmPC (Summary of Product Characteristics).

    Also known as: Xtandi

  • DrugAbirateroneStudies of AbirateroneAbiraterone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.

    Also known as: Zytiga

  • Carboplatin will be administered every 3rd week with an AUC (area under curve) = 5 with a dose calculated according to the Carboplatin AUC Dose calculation (Calvert formula):Dose (mg) = TargetAUC (mg/ml x min) x \[GFR ml/min + 25\].

  • DrugCabazitaxelStudies of CabazitaxelCabazitaxel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.

  • DrugDocetaxelStudies of DocetaxelDocetaxel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.

  • DrugRadium Ra 223 dichlorideStudies of Radium Ra 223 dichlorideRadium Ra 223 dichloride pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.

    Also known as: Xofigo

  • DrugNiraparib plus Abiraterone acetate plus Prednisone

    Drug pages: NiraparibStudies of NiraparibNiraparib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Abiraterone AcetateStudies of Abiraterone AcetateAbiraterone Acetate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · PrednisoneStudies of PrednisonePrednisone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Niraparib and Abiraterone acetate will be provided by Janssen and will be provided either as a fixed dose combination or as single agents. Detailed use of the study treatment including dose and dosages are described in the Investigator's brochures and SmPC.

    Also known as: Akeega

  • DrugCapivasertib plus Docetaxel

    Drug pages: CapivasertibStudies of CapivasertibCapivasertib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · DocetaxelStudies of DocetaxelDocetaxel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Capivasertib is provided by AstraZeneca and will be given in combination with Docetaxel. All subjects will be given up to ten 21-day docetaxel cycles. All subjects will receive Capivasertib, which will be administered as tablets taken twice a day orally, on a 4 days on/3 days off continuous schedule, commencing cycle one, day 2, until disease progression.

  • Detailed conditions for the use of the study treatments including dose and dosages are described in accordance with the marketing authorization in the SmPC (Summary of Product Characteristics).

    Also known as: Erleada

  • Detailed conditions for the use of the study treatments including dose and dosages are described in accordance with the marketing authorization in the SmPC (Summary of Product Characteristics).

    Also known as: Nubeqa

06

What researchers measure

Primary outcomes

  1. Progression free survival (PFS) in mCRPC

    Progression will be evaluated by the established international standards of the Prostate Cancer Working Group version 3 (PCWG3) and for soft tissue metastases (e.g. lung, liver and lymph nodes) according to the Response Evaluation Criteria in Solid Tumors (RECIST v. 1.1).

    Time frame: Until progressive disease or 60 months from start of treatment, whatever occurs first.

  2. Progression free survival (PFS) in mHSPC

    Time to development of castration-resistance, as defined by EAU guidelines (biochemical progression or radiologic progression)

    Time frame: From date of treatment start until the date of first documentation of progression, assessed up to 60 months

Secondary outcomes

  1. Treatment response rate in mCRPC

    Treatment response is evaluated according to PCWG3 and RECIST 1.1

    Time frame: 4 months after treatment start

  2. Overall survival (OS)

    OS is defined as time to death from any cause (overall and prostate cancer specific)

    Time frame: From enrolment to completion of study (60 months)

  3. Patient Reported Outcome Measures (PROM)

    QoL will be assessed using the EORTC QLQ-C30 instrument

    Time frame: From enrolment to completion of study (60 months)

  4. Cost-effectiveness

    Cost effectiveness will be assessed by using the EQ-5D-5L instrument to estimate health utilities. Treatment costs will be based on drug costs and reimbursement data.

    Time frame: From enrolment to completion of study (60 months)

  5. Number of Participants With Adverse Events as a Measure of Safety and Tolerability

    Common Terminology Criteria for Adverse Events (CTCAE) developed and maintained by the US National Cancer Institute will be used to record adverse events

    Time frame: From enrolment to completion of study (60 months)

  6. Treatment response rate in mHSPC

    Response rates at 6 months on therapy will be evaluated by the established standards of EAU Guidelines

    Time frame: 6 months after treatment start

07

Study locations

29 of 32 sites recruiting
08

References and documents

Publications

  • Crippa A, De Laere B, Discacciati A, Larsson B, Connor JT, Gabriel EE, Thellenberg C, Janes E, Enblad G, Ullen A, Hjalm-Eriksson M, Oldenburg J, Ost P, Lindberg J, Eklund M, Gronberg H. The ProBio trial: molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer. Trials. 2020 Jun 26;21(1):579. doi: 10.1186/s13063-020-04515-8. PubMed 32586393 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2019 (actual). Primary completion is estimated for Dec 2026, 94 months after the start.

Of 139 non-industry phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 99 months of starting (the median), counting those still running; a quarter within 57 and three quarters within 144. This study's planned 94 months is close to that.

Counting every sponsor, half of 266 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2019
First posted
Apr 4, 2019
StartActual
Feb 1, 2019
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Apr 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03903835
Collaborators
The Swedish Research Council, Kom Op Tegen Kanker, Janssen Pharmaceutica N.V., Belgium, AstraZeneca, Cancerfonden
Responsible party
Henrik Grönberg (Professor of Cancer Epidemiology, Karolinska Institutet) — Principal investigator
First posted
Apr 4, 2019
Start date
Feb 1, 2019
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Apr 9, 2025

Study contacts

Berit Larsson, MSc
Contact
berit.larsson@ki.se
+46 8 52482576
Henrik Grönberg, Professor
Contact
Henrik.gronberg@ki.se
+46 70 3411356
Henrik Grönberg, Professor
principal investigator · Karolinska Institutet
Martin Eklund, Professor
study director · Karolinska Institutet
Johan Lindberg, PhD
study director · Karolinska Institutet
Piet Ost, Professor
principal investigator · University Hospital Ghent, Belgium
Jan Oldenburg, Professor
principal investigator · University Hospital, Akershus
Ashkan Mortezavi, MD, PhD
principal investigator · University Hospital, Basel, Switzerland

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Enzalutamide · Abiraterone · Carboplatin · Docetaxel · Niraparib · Abiraterone Acetate · Prednisone · Capivasertib · Apalutamide · Darolutamide

Start the discussion